August 2024 – Page 3

Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases

8 months ago talkbio0Tagged Cardiovascular Diseases, Drug Development, Flagship, Kidney Diseases, Partnership, Pfizer, Pioneering, somatic genomics

Pfizer, Flagship Pioneering, Quotient Therapeutics, cardiovascular diseases, renal diseases, somatic genomics, drug development, partnership

UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development

8 months ago talkbio0Tagged California, development aspects, Gary Michelson, Immunology, Immunotherapy, research, Ucla, Vaccines

UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy

Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial

8 months ago talkbio0Tagged AbbVie, Antipsychotic Agents, Biosciences, Emraclidine, KarXT, Muscarinic Acetylcholine Receptor, Myers, NBI-1117568, Neurocrine, Schizophrenia, squibb

Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics

FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

8 months ago talkbio0Tagged Approved, cellular targeting, Comprehensive, Diagnostics, Gene Fusion, Illumina, Neoplasms, NTRK, pan-cancer, Pet Animal, Precision - temporal, RET protein, human, TruSight Oncology, United States Food and Drug Administration

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.